Navigation Links
Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
Date:12/6/2008

SAN FRANCISCO, Dec. 6 /PRNewswire/ -- Researchers today report that after the implementation of Medicare coverage limitations for erythropoiesis-stimulating agents (ESAs), a significantly greater proportion of anemic cancer patients who were on chemotherapy and who received ESAs needed blood transfusions and utilized more units of blood per patient than those patients who received ESAs prior to implementation of coverage limitations. The findings from this observational study will be presented at the 50th Annual Meeting of the American Society of Hematology on Saturday, December 6th at 9:00 a.m. PST.

In July 2007, the Centers for Medicare and Medicaid Services (CMS) issued coverage limitations, in the form of a National Coverage Determination (NCD), for the use of ESAs in anemic cancer patients receiving chemotherapy. An ongoing, prospective, observational study [Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) registry] is evaluating ESA-treated anemic cancer patients receiving chemotherapy. The present analyses were conducted using data from this study, focused on patients covered by Medicare before and after implementation of the CMS NCD for ESAs.

"We wanted to examine the potential impacts on transfusion patterns and hematologic changes in anemic Medicare patients receiving chemotherapy treated with ESAs before and after implementation of the ESA coverage limitations," said study director Chris L. Pashos, PhD, Vice President, Abt Bio-Pharma Solutions, Inc. "Our analyses found increased transfusion rates and greater blood utilization in anemic Medicare patients receiving chemotherapy and treated with ESAs after implementation of the ESA NCD compared with before implementation of the ESA NCD."

Study Methods and Results

Data from 288 Medicare patients (pre-NCD: 230, post-NCD: 58) from 41 sites included in the DOSE registry were analyzed. Data we
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
2. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
3. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
4. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
5. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
6. Gene Therapy Corrects Sickle Cell Disease in Laboratory Study
7. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
8. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
9. PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
10. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
11. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... N.Y. , Aug. 3, 2015 Par ... a conference call on Friday, August 7, 2015 at ... for the second quarter ended June 30, 2015.  Par ... available to the public in its filings with the ... information available on its website by following the instructions ...
(Date:8/3/2015)...   ConvergeHEALTH by Deloitte is announcing ... is expanding its year-long research collaboration with ... to include women,s health.  This ... generate real-world clinical insights in an effort to ... to expanding our work with Allergan to address ...
(Date:8/3/2015)... 2015 VWR (NASDAQ: VWR ), ... announces the redesign of its global website, www.vwr.com , ... visiting the new site, guests will enjoy enhanced content on ... images.  Each country site now includes: , ... menu; and , the ability to search by discipline/industry. ...
Breaking Medicine Technology:ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4VWR's New Website Redesign Provides Improved Functionality for Customers 2
... TUSTIN, Calif., Jan. 6, 2012 Radient Pharmaceuticals Corporation ... Vitro Diagnostic (IVD) cancer tests, today announced that ... will be launched with a print ad that ... throughout 2012.  These journals have high circulation among ...
... WAYNE, N.J., Jan. 6, 2012  Cascade Medical ... proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) ... tissue and bone repair, announced the sale of their ... ConMed Linvatec for the worldwide orthopedic, dental, and wound ...
Cached Medicine Technology:Radient Pharmaceuticals Announces New Advertisement for Oncology Publications 2Cascade Medical Enterprises, LLC Announces the Sale of Their Orthopedic Business 2
(Date:8/3/2015)... ... 2015 , ... BESLER Consulting today announced the firm has ... MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative work ... their Readmissions Analytics product was selected as one of four finalists in the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, ... Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can help ... , Annually, more than 8.6 million adverse drug events are reported in ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... retailer of nutritional supplements, has officially opened the polls for their eleventh ... the following categories:, ,     Brand of the Year (BPI ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... is thought to be the first man to have died ... Borders revealed that Norris'// home had been cordoned off. Norris ... tests conducted showed that he had died of anthrax. ... panic since anthrax is not transmitted from person to person. ...
... Officials in Nizamabad in Andhra Pradesh have hit on a ... HIV/AIDS. When thousands of residents opened their// newspapers this Independence ... the front page. ,"Earlier we distributed condoms at ... (tobacco) shops but we met with lukewarm response," said Ashok ...
... player in the Indian drug industry, has received a ... (FDA) for three// of its abbreviated new drug applications ... launching this product in the US through its exclusive ... release Wednesday. ,The FDA approvals for Cefotaxime ...
... are high in saturated and trans fats, a high ... rate of decline in thinking, learning// and memory abilities. ... for brain development and function, an imbalance of these ... brain plaques associated with Alzheimer’s disease. Previous studies have ...
... study published in the British Medical Journal, researchers at Oxford ... per cent in the consumption of common foods// containing trans ... in coronary heart disease. ,Trans fats are added ... is added to most fast foods, confectionary, sandwich spreads, and ...
... Ireland which will aim to bring some reprieve to ... the government to the tune of ?7m annually. ... checks of patient and prescription information and comparing them ... Northern Ireland has will be enabling the system, labeled ...
Cached Medicine News:Health News:High-Fat, Copper-Rich Diets Associated with Increased Rates of Cognitive Decline 2
...
Tip is bent towards port for downward irrigation. 25G x 7/8in (.50 x 16mm)...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 23G x 5/8in (.60 x 16mm)...
... designed for LASIK surgery and other types ... corneal interface and/or stromal bed. Flattened tip ... helps elevate the flap edge. Multiple ports ... (.40 x 22mm). Angled 90 degrees, 7mm ...
Medicine Products: